In this context, particular attention is warranted regarding the potential role of sodium-glucose cotransporter-2 (SGLT2) inhibitors [120], thiazolidinediones [121] and dipeptidyl peptidase 4 (DPP-4) inhibitors [122] which are used in the management of diabetes and have been demonstrated to reduce insulin resistance. The gene discussed is DPP4; the disease is diabetes mellitus.